GAINESVILLE, Fla., May 2, 2014 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq:AGTC), a clinical stage biotechnology company developing adeno-associated virus (AAV)-based gene therapies for the treatment of rare eye diseases, today announced that Guo-jie Ye, Ph. D., Director, Research and Pre-Clinical Studies, will present preclinical data related to the company's achromatopsia gene therapy program in an oral session at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting. ARVO will take place from May 4 – 8, 2014, at the Orlando Convention Center in Orlando, Fl.
Help employers find you! Check out all the jobs and post your resume.
